Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma

NCT01332617 is registered in ClinicalTrials.gov with University of Louisville as lead sponsor.

NCT NCT01332617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma
Lead sponsor
University of Louisville
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2011
Completion date
February 28, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma